# How Lipfendra, Inclisiran, and New Guidelines Are Changing Cholesterol Management
Three new developments are reshaping how doctors treat high cholesterol. Lipfendra, a combination medication pairing bempedoic acid with atorvastatin, offers a dual approach to lowering LDL cholesterol. Inclisiran, an injectable therapy that works through RNA interference, reduces cholesterol by silencing genes that control cholesterol production. Together with updated clinical guidelines, these options give patients and providers more paths to better outcomes.
Lipfendra targets two different points in the cholesterol pathway. Bempedoic acid blocks uric acid production while lowering cholesterol, while atorvastatin remains a proven statin. This combination addresses a real clinical gap: people who don't reach cholesterol targets on statin monotherapy alone often struggle with medication complexity.
Inclisiran represents a different strategy. Patients receive two initial injections, then maintenance doses twice yearly. The drug silences PCSK9 and ApoB genes, cutting LDL cholesterol by roughly 50 percent. Studies show inclisiran works especially well for patients who can't tolerate statins or need aggressive cholesterol reduction.
Updated guidelines now reflect these advances. Professional organizations increasingly recommend treating cholesterol as a complex problem requiring individualized risk assessment. Doctors now consider genetic factors, existing heart disease, and treatment response when selecting therapies. One-size-fits-all approaches give way to tailored protocols.
The practical impact matters for millions. Someone with familial hypercholesterolemia who previously had limited options now might use inclisiran. A patient on maximum statin doses who still has high LDL might benefit from Lipfendra's combination approach. These medicines don't replace lifestyle changes like diet and exercise, but they enhance what behavior modification can achieve